Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
2(29%)

Phase Distribution

Ph early_phase_1
1
14%
Ph phase_2
2
29%
Ph phase_1
3
43%
Ph phase_3
1
14%

Phase Distribution

4

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (14.3%)
Phase 13 (42.9%)
Phase 22 (28.6%)
Phase 31 (14.3%)

Trials by Status

not_yet_recruiting114%
terminated229%
completed457%

Recent Activity

Clinical Trials (7)

Drug Details

Intervention Type
DRUG
Total Trials
7